Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

S Tsimikas is named as an inventor of and receives royalties from patents and patent applications awarded to the University of California (CA, USA) for the use of oxidation-specific antibodies, is a cofounder and has equity interest in Atherotope, is a consultant to ISIS, Genzyme, Quest and Aterovax, and has received investigator-initiated grants from Merck and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.